关于优化再融资一揽子措施点评：扶优促新，定向开闸

Policy Overview - On February 9, 2026, the Shanghai and Shenzhen Stock Exchanges launched a package of measures to optimize refinancing, enhancing flexibility and convenience to better serve technological innovation[4]. - The China Securities Regulatory Commission (CSRC) issued a decision on January 29, 2026, modifying the applicable opinions on the registration management of securities issuance, establishing a systematic framework for introducing strategic investors in fixed-price placements[4]. Support for Quality Companies - Increased support for "quality" listed companies in refinancing, defined by governance, information disclosure standards, and market recognition, with funds directed towards emerging fields aligned with core business[4]. - The new measures aim to reduce disclosure and compliance costs for companies by allowing the use of previously disclosed information in applications[4]. Measures for Technological Innovation - Three key initiatives support refinancing for technology innovation companies: 1. Unified standards for "light asset" and "high R&D investment" across main and sci-tech boards, with 299 companies on the main board and 205 on the sci-tech board meeting the criteria, representing 9% and 34% of their respective sectors[4]. 2. Relaxation of financing intervals for unprofitable companies, allowing 35 companies, primarily in pharmaceuticals (14) and semiconductors (7), to initiate new financing after 6 months instead of the previous 18 months[4]. 3. Allowing companies facing share price declines to access financing through market-based methods, with 535 companies (approximately 9.76%) currently in a state of decline[4]. Strategic Investor Guidelines - The new framework for fixed-price placements requires strategic investors to engage in deep integration with listed companies, distinguishing them from short-term arbitrage investors[4]. - Strategic investors must hold at least 5% of the total share capital post-issuance, potentially granting them board representation and governance participation[4]. Risk Considerations - Risks include changes in fixed-price placement policies, slower-than-expected review processes, fluctuations in secondary market stock prices, and variations in placement pricing[4].